JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Exact Sciences Corporation (NASDAQ:EXAS), a leader in cancer diagnostics and medical laboratories with annual revenue of $2.76 billion and 10.37% year-over-year growth, announced today the appointment of Leslie Trigg to its Board of Directors. According to InvestingPro analysis, while currently not profitable, analysts expect the company to turn profitable this year. Ms. Trigg, with over 25 years of healthcare and medical device industry experience, will join as a Class II member with her term concluding at the 2026 annual shareholders meeting. With the company’s next earnings report due on May 1, 2025, and strong analyst consensus recommendations, investors can access deeper insights through InvestingPro’s comprehensive research reports.
The appointment fills the vacancy left by Kathleen Sebelius, who resigned on Monday for retirement purposes. The company clarified that Ms. Sebelius’s departure was not due to any disagreement regarding the company’s operations, policies, or practices.
Leslie Trigg is currently the CEO and Chair of the Board at Outset Medical (TASE:BLWV), Inc. (NASDAQ:OM) and has held leadership positions at several medical device firms. She also serves as Chair of the Board at the Medical Device Manufacturers Association. Her educational background includes a B.S. from Northwestern (NASDAQ:NWE) University and an M.B.A. from the University of California, Berkeley’s Haas School of Business.
As part of her director compensation, Ms. Trigg received a stock award valued at $375,000 in line with the company’s Non-Employee Director Compensation Policy. This policy was detailed in Exact Sciences’ Annual Report on Form 10-K filed on February 19, 2025.
Exact Sciences expressed its deepest gratitude to Ms. Sebelius for her distinguished service and contributions during her tenure on the board. The company’s choice to bring Ms. Trigg on board reflects its commitment to leadership with extensive experience in the healthcare industry. Despite trading at a high EBITDA multiple, InvestingPro data shows the company maintains strong liquidity with a current ratio of 2.15.
This news is based on a press release statement.
In other recent news, Exact Sciences has been the focus of several analyst updates and strategic developments. Mizuho (NYSE:MFG) initiated coverage on the company with an Outperform rating and a price target of $60, citing the anticipated launch of the Cologuard Plus test with improved sensitivity and specificity. Benchmark maintained its Buy rating with a $65 price target, despite revising its 2025 revenue and EBITDA forecasts downward. Stifel also reiterated a Buy rating, setting their price target at $67, aligning with the company’s guidance and highlighting potential growth from new product launches like Cologuard Plus and Oncodetect. TD Cowen expressed optimism, keeping an $86 price target and noting Exact Sciences’ conservative guidance, while identifying factors that could drive sales and EBITDA beyond expectations. The company is preparing for significant product launches in 2025, including the Oncodetect Molecular Residual Disease Test and the Cancerguard Multi-Cancer Early Detection Test. These developments are expected to contribute to Exact Sciences’ growth, with analysts showing confidence in the company’s strategic direction and product pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.